A novel radioimmunotherapy strategy has shown compelling efficacy in eliminating ovarian cancer stem cells in preclinical ...

The ARANOTE trial showed that adding darolutamide to ADT reduced the risk of progression or death by 46% in metastatic ...

The popular artificial sweetener sucralose may impair cancer immunotherapy by depleting arginine—an amino acid essential for ...

Gnosis has announced the launch of EdenDx, the first non-invasive, liquid-based cytology test for early endometrial cancer ...

A global study demonstrated that CAR-T cell therapy is linked to significantly increased risks of secondary cancers—8.9-fold ...

Researchers have enhanced cisplatin’s efficacy in advanced NSCLC by transplanting functional mitochondria from cardiomyocytes ...

Nuvisertib, an oral PIM1 kinase inhibitor from Sumitomo Pharma, has received Orphan Drug Designation from the EMA for ...

A new study published in Cancer Cell reveals that blocking a key nutrient-scavenging process in pancreatic tumors reprograms the tumor microenvironment—reducing fibrosis, enhancing T cell infiltration ...

Eli Lilly’s first-in-class non-covalent BTK inhibitor, demonstrated superior overall response rates compared to Imbruvica in ...

Nuvisertib, an oral PIM1 kinase inhibitor from Sumitomo Pharma, has received Orphan Drug Designation from the EMA for treating relapsed or refractory myelofibrosis—a rare blood cancer.